We’re thrilled to share that the Phase 1/2 ASPIRE-FTD clinical trial evaluating AVB-101, a potentially transformative investigational #GeneTherapy for people with #FrontotemporalDementia with GRN mutations, is now recruiting patients in the United States at The Ohio State University Wexner Medical Center. Learn more: https://lnkd.in/gcEQATSJ #FTD #Biotech #AviadoBio
AviadoBio
Biotechnology Research
London, England 10,723 followers
A revolution in gene therapy for neurodegenerative disorders.
About us
At AviadoBio, we are relentlessly chasing cures by translating groundbreaking science and precision delivery into life-changing medicines for people living with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). With our deep understanding of the brain and our suite of proprietary gene therapy platforms and delivery technologies, we are working relentlessly to overcome the challenges of delivering the right drug to the right place. Our innovative, neuroanatomy-led approach is designed to maximize the therapeutic potential of gene therapy to halt or potentially reverse neurodegenerative diseases. The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute.
- Website
-
http://www.aviadobio.com
External link for AviadoBio
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- London, England
- Type
- Privately Held
- Founded
- 2019
Locations
-
Primary
20 Water Street
London, England E14 9GG, GB
Employees at AviadoBio
Updates
-
We’re pleased to be recognized by Drug Discovery World as a contributor to the advancement of cell and #GeneTherapy research in neurodegenerative disease with the initiation of the Phase I/II ASPIRE-FTD clinical trial for people with frontotemporal dementia with GRN mutations. Read the full article here: https://lnkd.in/ej3YspBF #FrontotemporalDementia #AviadoBio
Neurodegenerative diseases are increasing at an alarming rate due to the ageing global population. There are a number of potentially groundbreaking cell and gene therapies (CGTs) currently being developed to address these increasingly prevalent conditions. Here are our top 5 from Asklepios BioPharmaceutical, Inc. (AskBio), NKGen Biotech, Inc., AviadoBio, Voyager Therapeutics, Inc. and Kenai Therapeutics. https://lnkd.in/ej3YspBF #drugdiscovery #cellandgenetherapy #neurodegenerativediseases
-
Our Aviators came together to support the My Name'5 Doddie Foundation by assembling race packets for their upcoming fundraiser. We’re grateful to be able to support this organization dedicated to helping improve the lives of those affected by Motor Neuron Disease (#MND). #GeneTherapyResearch
-
#ICYMI: Our Head of Preclinical Research Carlos Miranda presented preclinical data on AVB-101, our investigational #GeneTherapy for people with #FTD-GRN, at this year’s Alzheimer's Association® International Conference. View the poster here: https://lnkd.in/eM-Qdkf6 #FrontotemporalDementia #AAIC24
-
Attending this year’s Alzheimer's Association® International Conference? Carlos Miranda, Head of Preclinical Research, will be presenting pre-clinical data on AVB-101, our investigational #GeneTherapy in development for people with #FTD-GRN. Learn more about our science: https://lnkd.in/eSw7NZh3 #AAIC24 #FrontotemporalDementia
-
Our Chief Medical Officer Dr. David Cooper spoke with NeurologyLive to discuss the details of ASPIRE-FTD, a Ph. 1/2 clinical trial evaluating our investigational #GeneTherapy for #FrontotemporalDementia with GRN mutations (FTD-GRN). Learn more below. #BioTech #Dementia
David Cooper, MD, of AviadoBio, gave comment on some of the ongoing challenges associated with gene therapies in frontotemporal #dementia, and how the company will overcome these. https://lnkd.in/ecYh-Npv
Newly Initiated ASPIRE-FTD Trial Opens Door for Gene Therapy to Treat Frontotemporal Dementia
neurologylive.com
-
Our CEO, Lisa Deschamps, was in Washington, D.C. for the Alliance for Regenerative Medicine Congressional Fly-In. We loved learning about the latest updates in regenerative medicine and hearing from the event’s Keynote Speaker, Dr. Nicole Verdun.
Our 2024 Cell & Gene Congressional Fly-In came to a close yesterday, marking our most successful Fly-In yet! Throughout the course of Tuesday, we covered: ➡ 100+ offices ➡ 23 states Thank you to all of our advocates who came out this week to show support for patients who rely on the promise of cell and gene therapies. We especially thank our speakers and the 100+ offices from Congress and the administration for taking the time to hear our priorities. #CGFlyIn24
-
On #ResearchAppreciationDay and every day, we share our gratitude for our team of #Aviators who are working relentlessly to bring transformative medicines to people who need them. Learn more about AviadoBio here www.aviadobio.com #GeneTherapy #FTD #ALS
-
Today and every day we recognize the people affected by #ALS around the world. At AviadoBio, we are on a mission to develop potentially life-changing medicines for people with neurodegenerative disorders like ALS. Learn more about what you can do to support ALS research: https://lnkd.in/g3hTiWHs #ALSMNDWithoutBorders